文献速递膀胱癌与上尿路尿路上皮癌

血尿癌症风险评分联合Oncuria-Detect用于血尿评估患者

Hematuria Cancer Risk Score in Combination With Oncuria-Detect for Patients Undergoing Evaluation for Hematuria.
PubMed 文献 · Urology · 2025-08-20

本研究在365例血尿评估患者中评估HCRS联合尿液生物标志物Oncuria-Detect检测膀胱癌的性能。HCRS单独敏感性90.9%、特异性71.9%、AUC 0.890,联合Oncuria后特异性升至80.6%、AUC 0.909,提示联合策略可优化膀胱镜选择。

要点

  • HCRS单独检测膀胱癌敏感性90.9%、特异性71.9%、AUC 0.890。
  • HCRS联合Oncuria敏感性87.3%、特异性80.6%、AUC 0.909。
  • 联合策略在显微血尿患者中阴性预测值达98.7%。

核心结论

  • HCRS在血尿评估患者中对膀胱癌检测具有较强预测能力,联合Oncuria-Detect可进一步提升性能。

研究设计与样本

  • 前瞻性招募365例接受显微和肉眼血尿评估的患者,提供晨尿样本及临床信息,回顾性分析HCRS和Oncuria检测膀胱癌的敏感性、特异性及AUC。

主要发现

  • 最终队列中55例诊断为膀胱癌,310例为对照。
  • HCRS单独敏感性90.9%、特异性71.9%、AUC 0.890(95%CI: 0.832-0.948)、NPV 0.978。
  • Oncuria单独敏感性78.2%、特异性76.8%、AUC 0.838(95%CI: 0.770-0.906)、NPV 0.949。
  • HCRS联合Oncuria敏感性87.3%、特异性80.6%、AUC 0.909(95%CI: 0.855-0.962)、NPV 0.973。
  • 显微血尿患者中联合策略敏感性82.4%、NPV 98.7%。

临床怎么用

  • HCRS和Oncuria-Detect可在血尿初诊时进行,可能改善膀胱镜检查的患者选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the performance the Hematuria Cancer Risk Score (HCRS) in combination with the urine-based biomarker test Oncuria-Detect for the detection of bladder cancer in a cohort of patients referred for hematuria evaluation. METHODS: A cohort of 365 patients undergoing microscopic and gross hematuria evaluation were prospectively recruited to provide voided urine samples and pertinent clinical information. Then, retrospectively the primary outcome of sensitivity, specificity, and area under the curve (AUC) for HRCS and Oncuria for bladder cancer detection were reported. RESULTS: Of the final cohort, 55 patients were diagnosed with bladder cancer and 310 served as controls. In this cohort, HCRS alone achieved a sensitivity of 90.9%, specificity of 71.9% with an AUC of 0.890 (95%CI: 0.832-0.948) and NPV of 0.978. Oncuria achieved a comparable performance with sensitivity of 78.2%, specificity of 76.8%, and an AUC of 0.838 (95%CI: 0.770-0.906) with NPV of 0.949. Evaluation using the HCRS and Oncuria in combination produced a sensitivity of 87.3% and specificity of 80.6%. The combined approach had an AUC of 0.909 (95%CI: 0.855-0.962) and NPV of 0.973. For patients with microhematuria, HCRS and Oncuria together yielded a sensitivity of 82.4% and a negative predictive value of 98.7%. CONCLUSION: The HCRS achieves strong predictive power for the detection of bladder cancer in patients undergoing hematuria work up. The addition of the Oncuria-Detect test provides incremental improvement to this performance. Both tests can be performed at the initial primary care encounter for hematuria and may improve patient selection for cystoscopy.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Heard JR, Pagano I, Rosser C, et al. Hematuria Cancer Risk Score in Combination With Oncuria-Detect for Patients Undergoing Evaluation for Hematuria. Urology. 2025. PMID: 40846188. doi:10.1016/j.urology.2025.08.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。